Financial reports
10-K
2023 FY
Annual report
28 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
ARS
2022 FY
Annual report to shareholders
13 Apr 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
10-K
2021 FY
Annual report
24 Mar 22
Current reports
8-K
FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life
11 Mar 24
8-K
Regulation FD Disclosure
5 Mar 24
8-K
ADMA Biologics Announces CFO Transition
28 Feb 24
8-K
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
28 Feb 24
8-K
Other Events
21 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
8 Jan 24
8-K
ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
18 Dec 23
8-K
ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient
12 Dec 23
8-K
ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
16 Nov 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
7 Dec 22
424B5
Prospectus supplement for primary offering
6 Dec 22
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jul 22
S-8
Registration of securities for employees
22 Jul 22
Proxies
DEFA14A
Additional proxy soliciting materials
22 May 23
DEFA14A
Additional proxy soliciting materials
13 Apr 23
DEF 14A
Definitive proxy
13 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
DEFA14A
Additional proxy soliciting materials
8 Apr 21
DEF 14A
Definitive proxy
7 Apr 21
PRE 14A
Preliminary proxy
26 Mar 21
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEF 14A
Definitive proxy
29 Apr 20
Other
EFFECT
Notice of effectiveness
4 Aug 21
CORRESP
Correspondence with SEC
30 Jul 21
UPLOAD
Letter from SEC
3 Jun 21
SEC STAFF
SEC staff action: Order
10 Feb 20
SEC STAFF
SEC staff action: Order
3 Feb 20
EFFECT
Notice of effectiveness
16 Oct 19
CORRESP
Correspondence with SEC
10 Oct 19
UPLOAD
Letter from SEC
9 Oct 19
CT ORDER
Confidential treatment order
16 Apr 19
CT ORDER
Confidential treatment order
24 Sep 18
Ownership
4
STEVE ELMS
19 Mar 24
4
STEVE ELMS
15 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
SC 13G/A
TEACHERS ADVISORS, LLC
11 Mar 24
SC 13G/A
TIAA CREF INVESTMENT MANAGEMENT LLC
11 Mar 24
SC 13G/A
Nuveen Asset Management, LLC
11 Mar 24
4
BRIAN LENZ
8 Mar 24
4
Adam S Grossman
8 Mar 24
4
Adam S Grossman
4 Mar 24
4
BRIAN LENZ
4 Mar 24